Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera ® (olanzapine pamoate monohydrate)
ZypAdhera® (olanzapine pamoate): Oral Supplementation (label)
Oral olanzapine supplementation is not required, but if clinically necessary, the combined dose from olanzapine pamoate and oral olanzapine should not exceed the corresponding maximum oral olanzapine dose of 20 mg/day.
Supplementation with oral olanzapine was not authorised in double-blind clinical studies.1
Due to the slow dissolution of the olanzapine pamoate salt, which provides a slow continuous release of olanzapine that is complete approximately six to eight months after the last injection, supervision by a clinician, especially during the first 2 months after discontinuation of olanzapine pamoate, is needed when switching to another antipsychotic product and is considered medically appropriate.1
1. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.
Date of Last Review: May 01, 2019